Lurbinectedin with or without avelumab for small cell bladder cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This clinical trial tests a drug called lurbinectedin, given alone or with avelumab (an immunotherapy), for people with small cell bladder cancer or similar high-grade neuroendocrine tumors that have spread. The goal is to see if combining these drugs helps shrink or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell carcinoma or another high-grade neuroendocrine tumor of the bladder or urinary tract (excluding prostate tumors).
- Your cancer has spread to other parts of the body (metastatic) and has new or growing lesions.
- You are 18 years or older.
- You are in reasonably good health (able to perform daily activities with minimal assistance).
- Your blood counts, kidney, and liver function are within acceptable limits (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.
This trial tests a new combination of two drugs, lurbinectedin and durvalumab, for people with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard platinum-based chemotherapy along with durvalumab. The goal is to see if this combination can help control the cancer further.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests whether adding a new drug called lurbinectedin to paclitaxel (a standard chemotherapy) works better than paclitaxel alone for small cell lung cancer that has come back after prior treatment. The goal is to see if this combination helps patients live longer and controls their cancer better.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
Hear when a new Small Cell Carcinoma of the Bladder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.